← FDA DRUG APPROVALS

FDA ANDA · ANDA075140

TERAZOSIN HYDROCHLORIDE

Sponsor: PHARMOBEDIENT

APPLICATION
ANDA075140
TYPE
ANDA
ORIGINAL APPROVAL
2000-02-11
LATEST ACTION
2008-07-24
ROUTE
ORAL
DOSAGE FORM
CAPSULE
MARKETING STATUS
Discontinued

Products

TERAZOSIN HYDROCHLORIDEDiscontinued
TERAZOSIN HYDROCHLORIDE EQ 2MG BASE · CAPSULE · ORAL
TERAZOSIN HYDROCHLORIDEDiscontinued
TERAZOSIN HYDROCHLORIDE EQ 5MG BASE · CAPSULE · ORAL
TERAZOSIN HYDROCHLORIDEDiscontinued
TERAZOSIN HYDROCHLORIDE EQ 10MG BASE · CAPSULE · ORAL
TERAZOSIN HYDROCHLORIDEDiscontinued
TERAZOSIN HYDROCHLORIDE EQ 1MG BASE · CAPSULE · ORAL

Approval history

2008-07-24Labeling · Supplement 7AP
2002-08-22Labeling · Supplement 1AP
2000-02-11OriginalLetterAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →